Core Insights - The company reported third-quarter revenue of 1.341 billion, representing a year-on-year increase of 12.43% [1] - Net profit for the third quarter was 73.5149 million, showing a significant year-on-year growth of 123.23% [1] - For the first three quarters, total revenue reached 3.808 billion, reflecting a year-on-year growth of 17.32% [1] - However, net profit for the first three quarters was 178 million, which indicates a year-on-year decline of 15.14% [1] Financial Performance - Third-quarter revenue: 1.341 billion, up 12.43% year-on-year [1] - Third-quarter net profit: 73.5149 million, up 123.23% year-on-year [1] - Year-to-date revenue: 3.808 billion, up 17.32% year-on-year [1] - Year-to-date net profit: 178 million, down 15.14% year-on-year [1]

Core Insights - The company reported a third-quarter revenue of 221 million yuan, representing a year-on-year decline of 1.71% [1] - The net profit attributable to shareholders reached 15.53 million yuan, showing a significant year-on-year increase of 199.63% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 12.43 million yuan, reflecting a year-on-year growth of 178.52% [1] - The basic earnings per share stood at 0.08 yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 普 華 和 順 集 團 公 司 （ 於開曼群島註冊成立的有限公司） （股份代號：1358） 海外監管公告 附屬公司業績 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 普華和順集團公司（「本公司」，連同其附屬公司統稱為「本集團」）的非全資附屬公司四川睿 健醫療科技股份有限公司（ 股份代碼：874652（）「四川睿健醫療」）已於全國中小企業股份轉 讓系統（「全國中小企業股份轉讓系統」）指定披露平台(www.neeq.com.cn)公佈其截至二零二 四年十二月三十一日止年度的財務業績（ 經核數師審閱 ）。四川睿健醫療的財務報表乃按照 中國企業會計準則編製。 四 川 睿 健 醫 療 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 的 財 務 業 績（ 經 核 數 師 審 閱 ）摘 要 如 下。 收益表 | | 截至二零二四年 | 截至二零二三年 | | --- | - ...